





Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 29915/6177PCP	Serial No. 09/806,194
INFORMATION DISCLOSURE STATEMENT		Applicant Gurney et al.	
		Filing Date September 17, 2001	Group 1647



U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
CN	A1	5,424,205	6/13/95	Dovey et al.	435	226	
	A2	5,593,846	1/14/97	Schenk et al.	435	7.9	
	A3	5,733,768	3/31/98	Dixon et al.	435	226	
	A4	5,744,346	4/28/98	Chrysler et al.	435	226	
	A5	5,750,349	5/12/98	Suzuki et al.	435	7.1	
	A6	5,766,846	6/16/98	Schlossmacher et al.	435	6	
	A7	5,837,672	11/17/98	Schenk et al.	514	2	
	A8	5,849,560	12/15/98	Abraham	435	219	
	A9	5,942,400	8/24/99	Anderson et al.	435	7.1	
	A10	6,025,180	2/15/00	Powell et al.	435	219	
	A11	5,455,169	10/3/95	Mullan	435	240.2	
	A12	5,795,963	8/18/98	Mullan	435	350	
	A13	5,877,015	3/2/99	Hardy et al.	435	325	
	A14	6,211,428	4/3/01	Singh et al.	800	13	
	A15	6,221,645	4/24/01	Chrysler et al.	435	226	
	A16	6,245,884	6/12/01	Hook	530	300	
	A17	6,245,964	6/12/01	McLanogue et al.	800	12	
	A18	60/141,363	N/A	Lin et al.			6/28/99
	A19	60/168,060	N/A	Lin et al.			11/30/99
	A20	60/178,368	N/A	Lin et al.			1/27/00
	A21	60/210,292	N/A	Hong et al.			6/8/00
	A22	09/277,229	N/A	Citron et al.			3/26/99
	A23	6,313,268	11/6/01	Hook	530	350	
	A24	60/177,836	N/A	Lin et al.			1/25/00
	A25	60/119,571	N/A	Basi et al.			2/10/99
	A26	60/139,172	N/A	Anderson et al.			6/15/00
	A27	60/114,408	N/A	Basi et al.			12/13/98
	A28	09/404,578	N/A	Chrysler et al.			9/23/99
	A29	09/054,334	N/A	Anderson et al.			4/2/98
	A30	09/730,329	N/A	Anderson et al.			12/4/00
	A31	09/471,660	N/A	Anderson et al.			12/24/99
	A32	09/501,708	N/A	Anderson et al.			12/10/00
	A33	09/723,722	N/A	Anderson et al.			11/28/00
	A34	09/724,566	N/A	Anderson et al.			11/28/00
	A35	09/723,739	N/A	Anderson et al.			11/28/00
	A36	09/724,571	N/A	Anderson et al.			11/28/00
	A37	09/724,568	N/A	Anderson et al.			11/28/00
	A38	09/724,569	N/A	Anderson et al.			11/28/00
	A39	6,319,489	11/20/01	Powell et al.	435	69.1	
	A40	6,162,630	12/19/00	Powell et al.	435	219	


EXAMINER G. M. [Signature]	DATE CONSIDERED 7/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


only
refs. through
lined-
PRINT-
DO NOT
CONSIDERED

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 29915/6177PCP	Serial No. 09/806,194
INFORMATION DISCLOSURE STATEMENT			Applicant Gurney et al.	
			Filing Date September 17, 2001	Group 1647

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A41	6,319,689	11/20/01	Powell et al.	435	69.1	
	A42	6,358,725	03/19/02	Christie et al.	435	212	
	A43	6,361,975	03/26/02	Christie et al.	435	69.1	
	A44	6,545,127	04/08/03	Tang et al.	530	350	

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	WO 96/31122	10/10/96	PCT				
	B2	WO 96/40885	12/19/96	PCT				
	B3	WO 98/13488	4/2/98	PCT				
	B4	WO 98/21589	5/22/98	PCT				
	B5	EP 0848 062 A2	6/17/98	EPO				
	B6	WO 98/26059	6/18/98	PCT				
	B7	EP 0855 444 A2	7/29/98	EPO				
	B8	WO 99/34004	8/7/99	PCT				
	B9	WO 99/31236	6/24/99	PCT				
	B10	WO 99/46281	9/16/99	PCT				
	B11	WO 99/64587	12/16/99	PCT				
	B12	WO 00/23576	4/27/00	PCT				
	B13	WO 00/47618	08/17/00	PCT				
	B14	WO 00/58479	10/05/00	PCT				
	B15	WO 00/56871	9/28/00	PCT				
	B16	WO 00/68266	11/16/00	PCT				
	B17	WO 00/69262	11/23/00	PCT				
	B18	WO 01/00663	1/4/01	PCT				
	B19	WO 01/00665	1/4/01	PCT				
	B20	WO 01/29563	4/26/01	PCT				
	B21	WO 01/31054	5/3/01	PCT				
	B22	WO 01/36600	5/25/01	PCT				
	B23	WO 01/38487	5/31/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C1	Chyung et al. Novel β -Secretase Cleavage of β -Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells, <i>Journal of Cell Biology</i> , 138: 671-680 (1997).

EXAMINER 	DATE CONSIDERED 7/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 29915/6177PCP	Serial No. 09/806,194
INFORMATION DISCLOSURE STATEMENT		Applicant Gurney et al.	
		Filing Date September 17, 2001	Group 1647

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C2	Evin et al., Alzheimer's disease amyloid precursor protein (A β PP): proteolytic processing, secretases and β A4 amyloid production, <i>Amyloid; Int. J. Exp. Clin. Invest.</i> , 1: 263-280 (1997).	CONSIDERED; DO NOT PRINT. Used - through refs. only
C3	Haass et al., Amyloid β -peptide is Produced by Cultured Cells During Normal Metabolism, <i>Nature</i> , 359: 322-325 (1992).	
C4	Haass et al., β -Amyloid Peptide and 3-kDa Fragment are Derived by Distinct Cellular Mechanisms, <i>Journal of Biochemistry</i> , 268: 3021-3024 (February 15, 1993).	
C5	Haass et al., The Swedish Mutation Causes Early-Onset Alzheimer's Disease by β -Secretase Cleavage Within the Secretory Pathway, <i>Nature Medicine</i> , 12: 1291-1296 (1995).	
C6	Hirosawa et al., Characterization of cDNA Clones Selected by the GeneMark Analysis from Size-Fractionated cDNA Libraries From Human Brain, <i>DNA Res.</i> , 6(5): 329-336 (1999).	
C7	Hussain et al., Identification of a Novel Aspartic Protease (Asp ²¹) as β -Secretase, <i>Molecular and Cellular Neuroscience</i> , 14: 419-427 (1999).	
C8	Kang et al., The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor, <i>Nature</i> , 325: 733-736 (1987).	
C9	Kitaguchi et al., Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity, <i>Nature</i> , 331: 530-532 (1988).	
C10	Knops et al., Cell-type and Amyloid Precursor Protein-type Specific Inhibition of A β Release by Bafilomycin A1, a Selective Inhibitor of Vacuolar ATPases, <i>Journal of Biological Chemistry</i> , 270: 2419-2422 (1995).	
C11	Koo and Squazzo, Evidence that Production and Release of Amyloid β -Protein Involves the Endocytic Pathway, <i>Journal of Biological Chemistry</i> , 269: 17386-17389 (1994).	
C12	Ponte et al., A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors, <i>Nature</i> , 331: 525-527 (1988).	
C13	Seubert et al., Secretion of β -amyloid Precursor Protein Cleaved at the Amino Terminus of the β -amyloid Peptide, <i>Nature</i> , 361: 260-263 (1993).	
C14	Sinha et al., Purification and Cloning of Amyloid Precursor Protein β -Secretase from Human Brain, <i>Nature</i> , 402: 537-540 (1999).	
C15	Szececi, The Aspartic Proteases, <i>Scand. J. Clin. Lab. Invest.</i> , 52 (suppl. 210): 5-22 (1992).	
C16	Tanzi et al., Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease, <i>Nature</i> , 331: 528-530 (1988).	
C17	Vasser et al., β -secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE, <i>Science</i> , 286 (5440): 735-41 (1999).	
C18	Yan et al., Membrane-anchored Aspartyl Protease with Alzheimer's Disease β -Secretase Activity, <i>Nature</i> , 402: 533-537 (1999).	
C19	Zhao et al., β -Secretase Processing of the β -Amyloid Precursor Protein in Transgenic Mice Is Efficient in Neurons but Inefficient in Astrocytes, <i>Journal of Biological Chemistry</i> , 271: 31407-31411 (1996).	
C20	PCT Search report for PCT/US 99/20881	
C21	Mullan et al., A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of β -Amyloid, <i>Nature Genetics</i> 1: 345-347 (1992).	
C22	Elan and Pharmacia form Alzheimer's disease research collaboration in the area of Beta-Secretase, News 08/09/2000, www.elancorp.com.	

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	7/14/04
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	